Duality Advisers’s Arcus Biosciences RCUS Stock Holding History

Duality Advisers’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-29,050	Closed	-$590K	–	688
2023 Q2	$590K	Buy	+29,050	New	+$553K	0.07%	369
2023 Q1	–	Sell	-81,390	Closed	-$1.68M	–	727
2022 Q4	$1.68M	Buy	81,390 +56,589	+228%	+$1.56M	0.19%	192
2022 Q3	$649K	Buy	+24,801	New	+$656K	0.07%	380

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Duality Advisers's RCUS Position: Q3 2023 in Review

Duality Advisers sold out of Arcus Biosciences (RCUS) in Q3 2023, closing a stake of 29,050 shares — an estimated $590K sold.

Duality Advisers first reported a position in RCUS in Q3 2022 and held it in 3 quarters. The position peaked at $1.68M in Q4 2022. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2023.

Duality Advisers reported no remaining Arcus Biosciences position as of Q3 2023 after selling out during the quarter.
Duality Advisers sold 29,050 Arcus Biosciences shares in Q3 2023, an estimated $590K.
Duality Advisers first reported a position in Arcus Biosciences in Q3 2022 and held it in 3 quarters.
Duality Advisers's Arcus Biosciences position peaked at $1.68M in Q4 2022.
187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2023.

Based on Duality Advisers's 13F filing for Q3 2023, filed 2 Nov 2023.